Caribou Biosciences, Inc.

AI-generated fair value estimate for this company.

Method: Net-cash-plus-risk-adjusted-pipeline approach: $87.16M net cash / 107.21M shares = $0.81/share cash floor; plus an estimated $45M risk-adjusted NPV for the CRISPR-based allogeneic CAR-T pipeline (vispa-cel in Phase 1 for relapsed/refractory B-cell lymphoma, plus preclinical CB-011), reflecting a ~15% probability-weighted value against an estimated $300M peak-sales-derived un-risked NPV given the earlier clinical stage, or $0.42/share; total ~$1.23/share.

Reasoning: Caribou is an early-stage, pre-revenue cell-therapy biotech with no sustainable cash flow to discount, so a risk-adjusted net-asset-value framework is the standard and more accurate approach, appropriately reflecting the earlier (Phase 1/preclinical) stage of its pipeline relative to more advanced peers.